Article

McCabe C, Mishor Z. Antidepressant medications reduce subcortical-cortical resting-state functional connectivity in healthy volunteers. Neuroimage 57: 1317-1323

Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.
NeuroImage (Impact Factor: 6.36). 05/2011; 57(4):1317-23. DOI: 10.1016/j.neuroimage.2011.05.051
Source: PubMed

ABSTRACT

Studies have revealed abnormalities in resting-state functional connectivity in those with major depressive disorder specifically in areas such as the dorsal anterior cingulate, thalamus, amygdala, the pallidostriatum and subgenual cingulate. However, the effect of antidepressant medications on human brain function is less clear and the effect of these drugs on resting-state functional connectivity is unknown.
Forty volunteers matched for age and gender with no previous psychiatric history received either citalopram (SSRI; selective serotonergic reuptake inhibitor), reboxetine (SNRI; selective noradrenergic reuptake inhibitor) or placebo for 7 days in a double-blind design. Using resting-state functional magnetic resonance imaging and seed based connectivity analysis we selected the right nucleus accumbens, the right amygdala, the subgenual cingulate and the dorsal medial prefrontal cortex as seed regions. Mood and subjective experience were also measured before and after drug administration using self-report scales.
Despite no differences in mood across the three groups, we found reduced connectivity between the amygdala and the ventral medial prefrontal cortex in the citalopram group and the amygdala and the orbitofrontal cortex for the reboxetine group. We also found reduced striatal–orbitofrontal cortex connectivity in the reboxetine group.
These data suggest that antidepressant medications can decrease resting-state functional connectivity independent of mood change and in areas known to mediate reward and emotional processing in the brain. We conclude that hypothesis-driven seed based analysis of resting-state fMRI supports the proposition that antidepressant medications might work by normalising the elevated resting-state functional connectivity seen in depressed patients.

Download full-text

Full-text

Available from: Ciara Mccabe
  • Source
    • "Psychotropic medication likely influenced past DMN studies in ASD. For example, SSRIs reduced MPFC functional connectivity to medial temporal regions in healthy adults (McCabe and Mishor, 2011). Treatment with atypical antipsychotics in schizophrenia (Sambataro et al., 2010), and stimulants or SNRIs in ADHD (Marquand et al., 2011; Wilson et al., 2013) have increased PCC–MPFC functional connectivity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Functional pathology of the default mode network is posited to be central to social-cognitive impairment in autism spectrum disorders (ASD). Altered functional connectivity of the default mode network's midline core may be a potential endophenotype for social deficits in ASD. Generalizability from prior studies is limited by inclusion of medicated participants and by methods favoring restricted examination of network function. This study measured resting-state functional connectivity in 22 8–13 year-old non-medicated children with ASD and 22 typically developing controls using seed-based and network segregation functional connectivity methods. Relative to controls the ASD group showed both under- and over-functional connectivity within default mode and non-default mode regions, respectively. ASD symptoms correlated negatively with the connection strength of the default mode midline core—medial prefrontal cortex–posterior cingulate cortex. Network segregation analysis with the participation coefficient showed a higher area under the curve for the ASD group. Our findings demonstrate that the default mode network in ASD shows a pattern of poor segregation with both functional connectivity metrics. This study confirms the potential for the functional connection of the midline core as an endophenotype for social deficits. Poor segregation of the default mode network is consistent with an excitation/inhibition imbalance model of ASD.
    Full-text · Article · Aug 2015 · Clinical neuroimaging
  • Source
    • "Beyond its sympathetic property and peripheral effects within the autonomic nervous system, noradrenaline is one of the classical central neurotransmitters that plays a pivotal role in the pathophysiology of affective disorders (Schildkraut and Kety, 1967; Delgado and Moreno, 2000). There is only one study that previously investigated the impact of REB on rs-FC, revealing reduced striatal-orbitofrontal cortex connectivity compared to placebo (McCabe and Mishor, 2011). However, the intuitive influence of REB on the NE-pathway, as well as local resting state alterations, have not been investigated to date. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Various psychiatric populations are currently investigated with resting-state fMRI aiming to individualize diagnostics, treatment options and to improve treatment outcome. Many of these studies are conducted in large naturalistic samples providing rich insights regarding disease-related neural alterations but with the common psychopharmacological medication limiting interpretations of the results. We therefore investigated effects of common noradrenergic and anti-dopaminergic medication on local and global resting-state (rs) activity in healthy volunteers to further the understanding of the respective effects independent from disease-related alterations. Within a randomized, double-blind, placebo-controlled cross-over design, we investigated 19 healthy male subjects by resting-state fMRI after the intake of reboxetine (4mg/d), amisulpride (200mg/d) and placebo for 7 days each. Treatment-related differences in local and global rs-activity were measured by the fractional amplitude of low frequency fluctuations (fALFF) and resting-state functional connectivity (rs-FC). fALFF revealed alterations of local rs-activity within regions of the core noradrenergic pathway including the locus coeruleus under reboxetine correlated with its plasma levels. Moreover, reboxetine led to increased rs-FC between regions within this pathway, i.e. locus coeruleus, tectum, thalamus and amygdala. Amisulpride modulated local rs-activity of regions within the dopaminergic pathway with the altered signal in the putamen correlating with amisulpride plasma levels. Correspondingly, amisulpride increased rs-FC between regions of the dopaminergic pathway comprising substantia nigra and putamen. Our data provide evidence how psychopharmacological agents alter local and global rs-activity within the respective neuroanatomical pathways in healthy subjects that may help with interpretating 'big-data' in psychiatric populations. © The Author 2015. Published by Oxford University Press on behalf of CINP.
    Full-text · Article · Jul 2015 · The International Journal of Neuropsychopharmacology
  • Source
    • "Cognitive dysfunction might therefore be regarded as both, a state-and a trait-marker of depression. Conversely, since it has been suggested that SSRI and SNRI treatments can decrease the resting-state functional connectivity independent of mood change and in areas known to mediate reward and emotional processing in the brain (McCabe and Mishor, 2011), antidepressant treatment may also decrease cognitive function. For this reason, the importance of dissociating the cognitive consequences of MDD from those of SSRI treatment, and from cognitive evaluation of MDD subjects in a medicationnaïve state before the administration of antidepressants has been recently highlighted in a study by Herzallah et al. (2013a). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive dysfunction is of clinical significance and exerts longstanding implication on patients׳ function. Pharmacological and non-pharmacological treatments of cognitive dysfunction are emerging. This review evaluates pharmacological and non-pharmacological treatments of cognitive impairment primarily in the domains of memory, attention, processing speed and executive function in clinical depression. A total of 35 studies were retrieved from Pubmed, PsycInfo and Scopus after applying inclusion and exclusion criteria. Results show that various classes of antidepressants exert improving effects on cognitive function across several cognitive domains. Specifically, studies suggest that SSRIs, the SSRE tianeptine, the SNRI duloxetine, vortioxetine and other antidepressants such as bupropion and moclobemide may exert certain improving effects on cognitive function in depression, such as in learning and memory and executive function. Class-specific cognitive domains or specific dose–response relationships were not identified yet. The few non-pharmacological studies conducted employing cognitive orientated treatments and cognitive remediation therapy show promising results for the improvement of cognitive impairment in depression. However, several methodological constraints of studies limit generalizability of the results and caution the interpretation. Future direction should consider the development of a neuropsychological consensus cognitive battery to support the discovery, clinical assessment, comparison of studies and registration of new agents in clinical depression.
    Full-text · Article · Sep 2014 · Psychiatry Research
Show more